On March 1, 2024 Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, reported that management will participate in the following investor conferences in March (Press release, Immunocore, MAR 1, 2024, View Source [SID1234640698]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen 44th Annual Healthcare Conference

Fireside Chat: Tuesday, March 5, 2024, at 11:10 a.m. EST

Leerink Partners Global Biopharma Conference

1×1 and small group meetings: Tuesday, March 12, 2024

Jefferies Biotech on the Bay

1×1 and small group meetings: Wednesday, March 13, 2024

Barclays 26th Annual Global Healthcare Conference
Fireside Chat: Thursday, March 14, 2024, at 9:30 a.m. EST

Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.